Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability

Background Although recovery from relapses in MS appears to contribute to disability, it has largely been ignored as a treatment endpoint and disability predictor. Objective To identify demographic and clinical predictors of relapse recovery in the first 3 years and examine its contribution to 10-ye...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Multiple sclerosis journal - experimental, translational and clinical translational and clinical, 2021-04, Vol.7 (2), p.20552173211015503-20552173211015503
Hauptverfasser: Sotiropoulos, Marinos G, Lokhande, Hrishikesh, Healy, Brian C, Polgar-Turcsanyi, Mariann, Glanz, Bonnie I, Bakshi, Rohit, Weiner, Howard L, Chitnis, Tanuja
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 20552173211015503
container_issue 2
container_start_page 20552173211015503
container_title Multiple sclerosis journal - experimental, translational and clinical
container_volume 7
creator Sotiropoulos, Marinos G
Lokhande, Hrishikesh
Healy, Brian C
Polgar-Turcsanyi, Mariann
Glanz, Bonnie I
Bakshi, Rohit
Weiner, Howard L
Chitnis, Tanuja
description Background Although recovery from relapses in MS appears to contribute to disability, it has largely been ignored as a treatment endpoint and disability predictor. Objective To identify demographic and clinical predictors of relapse recovery in the first 3 years and examine its contribution to 10-year disability and MRI outcomes. Methods Relapse recovery was retrospectively assessed in 360 patients with MS using the return of the Expanded Disability Status Scale (EDSS), Functional System Scale and neurologic signs to baseline at least 6 months after onset. Univariate and multivariable models were used to associate recovery with demographic and clinical factors and predict 10-year outcomes. Results Recovery from relapses in the first 3 years was better in patients who were younger, on disease-modifying treatment, with a longer disease duration and without bowel or bladder symptoms. For every incomplete recovery, 10-year EDSS increased by 0.6 and 10-year timed 25-foot walk increased by 0.5 s. These outcomes were also higher with older age and higher baseline BMI. Ten-year MRI brain atrophy was associated only with older age, and MRI lesion volume was only associated with smoking. Conclusions Early initiation of disease-modifying treatment in MS was associated with improved relapse recovery, which in turn prevented long-term disability.
doi_str_mv 10.1177/20552173211015503
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8165535</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_20552173211015503</sage_id><sourcerecordid>2539524042</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466t-3f0e44c53a7fda8cc90bfdc6ae687d4edffe5e5ee551a0555bc1ecde388709223</originalsourceid><addsrcrecordid>eNp1kV1LHTEQhkNpqWL9Ad6UQG96szafmz29KBSxHyAIotchm8weI9nkNMkK5983h2PVtkguEt555p2ZDEInlJxSqtQnRqRkVHFGKaFSEv4KHe60bie-fvY-QMel3BHSqL6J9C064IISIRQ9RO4KgtkUwBlsuoe8xT7ieQnVbwLgYgPkVHz5jM-nCWzFacI1g6kzxIpNdNimWLMfl-pTxDXhkOK6q5Bn7Hwxow--bt-hN5MJBY4f7iN08-38-uxHd3H5_efZ14vOir6vHZ8ICGElN2pyZrB2RcbJ2d5APygnwLUWZDsgJTVtOjlaCtYBHwZFVozxI_Rl77tZxhmcbT1mE_Qm-9nkrU7G678j0d_qdbrXA-2l5LIZfHwwyOnXAqXq2RcLIZgIaSmaSb6STBCxq_XhH_QuLTm28RollBCMqaFRdE_Z9o0lw_TYDCV6t0b93xpbzvvnUzxm_FlaA073QDFreCr7suNvGRynOA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2547442278</pqid></control><display><type>article</type><title>Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability</title><source>PMC (PubMed Central)</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Sotiropoulos, Marinos G ; Lokhande, Hrishikesh ; Healy, Brian C ; Polgar-Turcsanyi, Mariann ; Glanz, Bonnie I ; Bakshi, Rohit ; Weiner, Howard L ; Chitnis, Tanuja</creator><creatorcontrib>Sotiropoulos, Marinos G ; Lokhande, Hrishikesh ; Healy, Brian C ; Polgar-Turcsanyi, Mariann ; Glanz, Bonnie I ; Bakshi, Rohit ; Weiner, Howard L ; Chitnis, Tanuja</creatorcontrib><description>Background Although recovery from relapses in MS appears to contribute to disability, it has largely been ignored as a treatment endpoint and disability predictor. Objective To identify demographic and clinical predictors of relapse recovery in the first 3 years and examine its contribution to 10-year disability and MRI outcomes. Methods Relapse recovery was retrospectively assessed in 360 patients with MS using the return of the Expanded Disability Status Scale (EDSS), Functional System Scale and neurologic signs to baseline at least 6 months after onset. Univariate and multivariable models were used to associate recovery with demographic and clinical factors and predict 10-year outcomes. Results Recovery from relapses in the first 3 years was better in patients who were younger, on disease-modifying treatment, with a longer disease duration and without bowel or bladder symptoms. For every incomplete recovery, 10-year EDSS increased by 0.6 and 10-year timed 25-foot walk increased by 0.5 s. These outcomes were also higher with older age and higher baseline BMI. Ten-year MRI brain atrophy was associated only with older age, and MRI lesion volume was only associated with smoking. Conclusions Early initiation of disease-modifying treatment in MS was associated with improved relapse recovery, which in turn prevented long-term disability.</description><identifier>ISSN: 2055-2173</identifier><identifier>EISSN: 2055-2173</identifier><identifier>DOI: 10.1177/20552173211015503</identifier><identifier>PMID: 34104471</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Cohort analysis ; Disability ; Medical prognosis ; Multiple sclerosis ; Original Research Paper</subject><ispartof>Multiple sclerosis journal - experimental, translational and clinical, 2021-04, Vol.7 (2), p.20552173211015503-20552173211015503</ispartof><rights>The Author(s) 2021</rights><rights>The Author(s) 2021.</rights><rights>The Author(s) 2021. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2021 2021 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c466t-3f0e44c53a7fda8cc90bfdc6ae687d4edffe5e5ee551a0555bc1ecde388709223</citedby><cites>FETCH-LOGICAL-c466t-3f0e44c53a7fda8cc90bfdc6ae687d4edffe5e5ee551a0555bc1ecde388709223</cites><orcidid>0000-0002-3032-7069 ; 0000-0001-5272-2425 ; 0000-0001-8601-5534 ; 0000-0002-9897-4422</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165535/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165535/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34104471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sotiropoulos, Marinos G</creatorcontrib><creatorcontrib>Lokhande, Hrishikesh</creatorcontrib><creatorcontrib>Healy, Brian C</creatorcontrib><creatorcontrib>Polgar-Turcsanyi, Mariann</creatorcontrib><creatorcontrib>Glanz, Bonnie I</creatorcontrib><creatorcontrib>Bakshi, Rohit</creatorcontrib><creatorcontrib>Weiner, Howard L</creatorcontrib><creatorcontrib>Chitnis, Tanuja</creatorcontrib><title>Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability</title><title>Multiple sclerosis journal - experimental, translational and clinical</title><addtitle>Mult Scler J Exp Transl Clin</addtitle><description>Background Although recovery from relapses in MS appears to contribute to disability, it has largely been ignored as a treatment endpoint and disability predictor. Objective To identify demographic and clinical predictors of relapse recovery in the first 3 years and examine its contribution to 10-year disability and MRI outcomes. Methods Relapse recovery was retrospectively assessed in 360 patients with MS using the return of the Expanded Disability Status Scale (EDSS), Functional System Scale and neurologic signs to baseline at least 6 months after onset. Univariate and multivariable models were used to associate recovery with demographic and clinical factors and predict 10-year outcomes. Results Recovery from relapses in the first 3 years was better in patients who were younger, on disease-modifying treatment, with a longer disease duration and without bowel or bladder symptoms. For every incomplete recovery, 10-year EDSS increased by 0.6 and 10-year timed 25-foot walk increased by 0.5 s. These outcomes were also higher with older age and higher baseline BMI. Ten-year MRI brain atrophy was associated only with older age, and MRI lesion volume was only associated with smoking. Conclusions Early initiation of disease-modifying treatment in MS was associated with improved relapse recovery, which in turn prevented long-term disability.</description><subject>Cohort analysis</subject><subject>Disability</subject><subject>Medical prognosis</subject><subject>Multiple sclerosis</subject><subject>Original Research Paper</subject><issn>2055-2173</issn><issn>2055-2173</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp1kV1LHTEQhkNpqWL9Ad6UQG96szafmz29KBSxHyAIotchm8weI9nkNMkK5983h2PVtkguEt555p2ZDEInlJxSqtQnRqRkVHFGKaFSEv4KHe60bie-fvY-QMel3BHSqL6J9C064IISIRQ9RO4KgtkUwBlsuoe8xT7ieQnVbwLgYgPkVHz5jM-nCWzFacI1g6kzxIpNdNimWLMfl-pTxDXhkOK6q5Bn7Hwxow--bt-hN5MJBY4f7iN08-38-uxHd3H5_efZ14vOir6vHZ8ICGElN2pyZrB2RcbJ2d5APygnwLUWZDsgJTVtOjlaCtYBHwZFVozxI_Rl77tZxhmcbT1mE_Qm-9nkrU7G678j0d_qdbrXA-2l5LIZfHwwyOnXAqXq2RcLIZgIaSmaSb6STBCxq_XhH_QuLTm28RollBCMqaFRdE_Z9o0lw_TYDCV6t0b93xpbzvvnUzxm_FlaA073QDFreCr7suNvGRynOA</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Sotiropoulos, Marinos G</creator><creator>Lokhande, Hrishikesh</creator><creator>Healy, Brian C</creator><creator>Polgar-Turcsanyi, Mariann</creator><creator>Glanz, Bonnie I</creator><creator>Bakshi, Rohit</creator><creator>Weiner, Howard L</creator><creator>Chitnis, Tanuja</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>AFRWT</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3032-7069</orcidid><orcidid>https://orcid.org/0000-0001-5272-2425</orcidid><orcidid>https://orcid.org/0000-0001-8601-5534</orcidid><orcidid>https://orcid.org/0000-0002-9897-4422</orcidid></search><sort><creationdate>20210401</creationdate><title>Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability</title><author>Sotiropoulos, Marinos G ; Lokhande, Hrishikesh ; Healy, Brian C ; Polgar-Turcsanyi, Mariann ; Glanz, Bonnie I ; Bakshi, Rohit ; Weiner, Howard L ; Chitnis, Tanuja</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466t-3f0e44c53a7fda8cc90bfdc6ae687d4edffe5e5ee551a0555bc1ecde388709223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cohort analysis</topic><topic>Disability</topic><topic>Medical prognosis</topic><topic>Multiple sclerosis</topic><topic>Original Research Paper</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sotiropoulos, Marinos G</creatorcontrib><creatorcontrib>Lokhande, Hrishikesh</creatorcontrib><creatorcontrib>Healy, Brian C</creatorcontrib><creatorcontrib>Polgar-Turcsanyi, Mariann</creatorcontrib><creatorcontrib>Glanz, Bonnie I</creatorcontrib><creatorcontrib>Bakshi, Rohit</creatorcontrib><creatorcontrib>Weiner, Howard L</creatorcontrib><creatorcontrib>Chitnis, Tanuja</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Multiple sclerosis journal - experimental, translational and clinical</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sotiropoulos, Marinos G</au><au>Lokhande, Hrishikesh</au><au>Healy, Brian C</au><au>Polgar-Turcsanyi, Mariann</au><au>Glanz, Bonnie I</au><au>Bakshi, Rohit</au><au>Weiner, Howard L</au><au>Chitnis, Tanuja</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability</atitle><jtitle>Multiple sclerosis journal - experimental, translational and clinical</jtitle><addtitle>Mult Scler J Exp Transl Clin</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>7</volume><issue>2</issue><spage>20552173211015503</spage><epage>20552173211015503</epage><pages>20552173211015503-20552173211015503</pages><issn>2055-2173</issn><eissn>2055-2173</eissn><abstract>Background Although recovery from relapses in MS appears to contribute to disability, it has largely been ignored as a treatment endpoint and disability predictor. Objective To identify demographic and clinical predictors of relapse recovery in the first 3 years and examine its contribution to 10-year disability and MRI outcomes. Methods Relapse recovery was retrospectively assessed in 360 patients with MS using the return of the Expanded Disability Status Scale (EDSS), Functional System Scale and neurologic signs to baseline at least 6 months after onset. Univariate and multivariable models were used to associate recovery with demographic and clinical factors and predict 10-year outcomes. Results Recovery from relapses in the first 3 years was better in patients who were younger, on disease-modifying treatment, with a longer disease duration and without bowel or bladder symptoms. For every incomplete recovery, 10-year EDSS increased by 0.6 and 10-year timed 25-foot walk increased by 0.5 s. These outcomes were also higher with older age and higher baseline BMI. Ten-year MRI brain atrophy was associated only with older age, and MRI lesion volume was only associated with smoking. Conclusions Early initiation of disease-modifying treatment in MS was associated with improved relapse recovery, which in turn prevented long-term disability.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>34104471</pmid><doi>10.1177/20552173211015503</doi><orcidid>https://orcid.org/0000-0002-3032-7069</orcidid><orcidid>https://orcid.org/0000-0001-5272-2425</orcidid><orcidid>https://orcid.org/0000-0001-8601-5534</orcidid><orcidid>https://orcid.org/0000-0002-9897-4422</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2055-2173
ispartof Multiple sclerosis journal - experimental, translational and clinical, 2021-04, Vol.7 (2), p.20552173211015503-20552173211015503
issn 2055-2173
2055-2173
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8165535
source PMC (PubMed Central); DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals
subjects Cohort analysis
Disability
Medical prognosis
Multiple sclerosis
Original Research Paper
title Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T07%3A37%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relapse%20recovery%20in%20multiple%20sclerosis:%20Effect%20of%20treatment%20and%20contribution%20to%20long-term%20disability&rft.jtitle=Multiple%20sclerosis%20journal%20-%20experimental,%20translational%20and%20clinical&rft.au=Sotiropoulos,%20Marinos%20G&rft.date=2021-04-01&rft.volume=7&rft.issue=2&rft.spage=20552173211015503&rft.epage=20552173211015503&rft.pages=20552173211015503-20552173211015503&rft.issn=2055-2173&rft.eissn=2055-2173&rft_id=info:doi/10.1177/20552173211015503&rft_dat=%3Cproquest_pubme%3E2539524042%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2547442278&rft_id=info:pmid/34104471&rft_sage_id=10.1177_20552173211015503&rfr_iscdi=true